Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Acrocephalosyndactylia × derazantinib × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Liver Neoplasms 2 Cholangiocarcinoma 2 Biliary Tract Neoplasms 2 Urinary Bladder Neoplasms 1 Neoplasms 1 Carcinoma, Transitional Cell 1 Bile Duct Neoplasms 1 Acrocephalosyndactylia 1

Interventions

pemigatinib 4 infigratinib 1 erdafitinib 1 derazantinib 1 atezolizumab 1 Rogaratinib 1 INCB 54828-101 1 Drug Combinations 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04045613 2023-10-13

FIDES-02

Basilea Pharmaceutica

Phase 1/2 Completed

95 enrolled 25 charts

Acrocephalosyndactylia, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡